Navigation Links
Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
Date:3/4/2013

FALLS CHURCH, Va., March 4, 2013 /PRNewswire/ -- One of the most critical challenges confronting the pharmaceutical industry is developing patient-friendly delivery systems for the growing biologics market, which currently totals $150 billion worldwide.  As the population ages, and the incidence rate of chronic indications rises globally, the market for biologics is expected to increase at a rate of nearly 10 percent annually. Biologic therapies typically require parenteral delivery due to their large size; however, injections are often painful for the patient, have a high risk of needle-stick injury, and require administration by a healthcare professional.  Consequently, there is a need to develop patient-friendly delivery methods for biologics that are convenient, safe, and increase patient compliance. Drug companies are actively seeking novel devices to make it easier for patients to self-administer drugs. By combining the drug formulation with a device, companies also have the opportunity to differentiate existing drugs as well as novel products in the pipeline.

Arina Paoli , Global Marketing Communications Manager for 3M, explains that the growing biologics market is driving the need for innovated delivery devices including microneedles. "We believe microneedle technologies will play a key role in the growth of the biologics market. We are seeing companies explore our MTS microneedle technologies to treat chronic conditions, such as rheumatoid arthritis, because this new delivery system has the potential to improve compliance and be easier to administer for both patients and caregivers," states Paoli.

To address these critical needs and identify business opportunities in this rapidly growing sector, Technology Catalysts International has launched a new Technology and Business Review on Next- Generation Self-Administered Drug-Device Combinations: New Technologies and Business Opportunities. This report focuses on the following leading delivery systems that will play a transformational role in optimizing delivery of biologics and promoting self-administration and enhanced patient compliance:

  • Autoinjectors and pen injectors
  • Prefilled syringes
  • Active transdermal devices, with a focus on microneedles
  • Inhalers

This report highlights the important regulatory approval process for drug-device combination products in the US, EU, and Japan. Important device design considerations, market trends, future applications, and challenges to developing drug-device combinations are also discussed. TCI's new report on Next-Generation Self-Administered Drug-Device Combinations will be made available online. Online features include:

  • Technology profiles updated in real time
  • A searchable database of technology profiles
  • Recent news on new product launches, licensing agreements, and collaborations

For complete report prospectus, pricing, and ordering information, please refer to:

http://www.technology-catalysts.com/reports_services/ddc.asp

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence with a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes. TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:

Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0257
arastogi@technology-catalysts.com
http://www.technology-catalysts.com


'/>"/>
SOURCE Technology Catalysts International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
2. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
3. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
4. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
5. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
6. MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
7. Remedy Informatics to Debut SpecimenTrack, Next-Generation Biorepository Software at ISBER 2012 Annual Meeting
8. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
9. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
10. HCG Injection Provider Posts Customer Testimonials on Ushcginjections.com Reviews Page
11. Nonin Medical Selected as Exclusive Provider of Cerebral/Somatic Oximetry Systems to Leading Pediatric Hospitals in Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017 AccuGenomics, Inc., a diagnostic company based ... that the company has provided an AccuKit to the ... at Chapel Hill and to Qura Therapeutics for evaluation ... quantify HIV reservoir and viral expression in human CD4+ ... Cure Center is a joint initiative between the University ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... of their recently launched community enrichment program. Partnering once again with Boys & ... Superstar competition to help find the area’s very own American Idol. With all ...
(Date:8/16/2017)... PA (PRWEB) , ... August 16, 2017 , ... A ... it has successfully opened clubfoot clinics in all 29 Indian states—bringing the country one ... clinic in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... company based in Vero Beach, announced today that two of their associates were ... that represents professionally managed senior living communities in Florida. The awards were announced ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... men and women to train as hospice volunteers. Volunteers provide much needed joy, ... over 30 years, the agency has trained volunteers to be vital members of ...
Breaking Medicine News(10 mins):